TUXEDO-1: trastuzumab deruxtecan for the treatment of HER2-positive breast cancer brain metastases

TUXEDO-1: trastuzumab deruxtecan for the treatment of HER2-positive breast cancer brain metastases

The latest news on the management of breast cancer patients with brain metastasesПодробнее

The latest news on the management of breast cancer patients with brain metastases

TUXEDO-1: QoL and neurocognitive function in HER2-positive BC w/ brain metastasis treated with T-DXdПодробнее

TUXEDO-1: QoL and neurocognitive function in HER2-positive BC w/ brain metastasis treated with T-DXd

TUXEDO-1: T-DXd for patients with HER2-positive breast cancer and brain metastasisПодробнее

TUXEDO-1: T-DXd for patients with HER2-positive breast cancer and brain metastasis

2021 San Antonio Breast Cancer Symposium Update on MBC | 2021-2022 EMBRACE MBC Virtual Forum SeriesПодробнее

2021 San Antonio Breast Cancer Symposium Update on MBC | 2021-2022 EMBRACE MBC Virtual Forum Series

Therapeutic landscape for patients with HER2-positive breast cancer with active brain metastasesПодробнее

Therapeutic landscape for patients with HER2-positive breast cancer with active brain metastases

Trastuzumab Deruxtecan for the Treatment of HER2+ Breast CancerПодробнее

Trastuzumab Deruxtecan for the Treatment of HER2+ Breast Cancer

Trastuzumab deruxtecan in patients with breast cancer and brain metastases in DESTINY-Breast01Подробнее

Trastuzumab deruxtecan in patients with breast cancer and brain metastases in DESTINY-Breast01